Stock Track | Ultragenyx Pharmaceutical Plunges 5.32% After-Hours on Earnings Miss, Weak Guidance and Restructuring Plan

Stock Track

Feb 13

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) experienced a significant after-hours plunge of 5.32% following the release of its fourth-quarter and full-year 2025 financial results.

The biopharmaceutical company reported a quarterly net loss of $1.29 per share, which was wider than the $1.09 loss per share anticipated by analysts polled by FactSet. While revenue of $207 million for the quarter surpassed expectations, the company's forward-looking guidance disappointed investors.

For 2026, Ultragenyx issued revenue guidance for its current products in the range of $730 million to $760 million, falling short of the analyst consensus estimate of $791.3 million. Concurrently, the company announced a strategic restructuring plan, including a 10% reduction of its workforce affecting approximately 130 employees, as it aims to chart a path to profitability by 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1153298525"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1153298525\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1153298525?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 07:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153298525","market":"nz","top_or_hot":-1,"title":"Stock Track | Ultragenyx Pharmaceutical Plunges 5.32% After-Hours on Earnings Miss, Weak Guidance and Restructuring Plan","media":"Stock Track","content":"<p>Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) experienced a significant after-hours plunge of 5.32% following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical company reported a quarterly net loss of $1.29 per share, which was wider than the $1.09 loss per share anticipated by analysts polled by FactSet. While revenue of $207 million for the quarter surpassed expectations, the company's forward-looking guidance disappointed investors.</p><p>For 2026, Ultragenyx issued revenue guidance for its current products in the range of $730 million to $760 million, falling short of the analyst consensus estimate of $791.3 million. Concurrently, the company announced a strategic restructuring plan, including a 10% reduction of its workforce affecting approximately 130 employees, as it aims to chart a path to profitability by 2027.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ultragenyx Pharmaceutical Plunges 5.32% After-Hours on Earnings Miss, Weak Guidance and Restructuring Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ultragenyx Pharmaceutical Plunges 5.32% After-Hours on Earnings Miss, Weak Guidance and Restructuring Plan\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-13 07:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) experienced a significant after-hours plunge of 5.32% following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The biopharmaceutical company reported a quarterly net loss of $1.29 per share, which was wider than the $1.09 loss per share anticipated by analysts polled by FactSet. While revenue of $207 million for the quarter surpassed expectations, the company's forward-looking guidance disappointed investors.</p><p>For 2026, Ultragenyx issued revenue guidance for its current products in the range of $730 million to $760 million, falling short of the analyst consensus estimate of $791.3 million. Concurrently, the company announced a strategic restructuring plan, including a 10% reduction of its workforce affecting approximately 130 employees, as it aims to chart a path to profitability by 2027.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RARE","symbol_name":"Ultragenyx Pharmaceutical Inc","start_time":0,"source_url":"","article_id":"1153298525","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153298525","pubTimestamp":1770937261,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) experienced a significant after-hours plunge of 5.32% following the release of its fourth-quarter and full-year 2025 financial results.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RARE":"Ultragenyx Pharmaceutical Inc"},"translate_title":"个股追踪|Ultragenyx制药盘后暴跌5.32%因盈利未达预期、指引及重组计划疲弱","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RARE":1},"content_text":"Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) experienced a significant after-hours plunge of 5.32% following the release of its fourth-quarter and full-year 2025 financial results.The biopharmaceutical company reported a quarterly net loss of $1.29 per share, which was wider than the $1.09 loss per share anticipated by analysts polled by FactSet. While revenue of $207 million for the quarter surpassed expectations, the company's forward-looking guidance disappointed investors.For 2026, Ultragenyx issued revenue guidance for its current products in the range of $730 million to $760 million, falling short of the analyst consensus estimate of $791.3 million. Concurrently, the company announced a strategic restructuring plan, including a 10% reduction of its workforce affecting approximately 130 employees, as it aims to chart a path to profitability by 2027.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}